Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 11, 2021 06:02 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Present at Upcoming Conferences

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a...
December 15, 2020 08:05 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
November 17, 2020 16:27 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch –– Clayton Fletcher, Head of Business Development & Strategic Planning, to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE...
October 29, 2020 16:36 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
September 28, 2020 08:45 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037

EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
September 15, 2020 07:18 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020

Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
August 04, 2020 16:10 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
July 15, 2020 08:05 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million

EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
June 02, 2020 08:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...
May 01, 2020 08:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders

EXTON, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of...